Oral pill dramatically cuts symptom relief time for hereditary angioedema attacks

A new oral treatment for hereditary angioedema (HAE) attacks is showing impressive results. The phase 3 RAPIDe-3 trial, published in The Lancet, found that deucrictibant immediate-release — a bradykinin B2 receptor antagonist taken as a single 20 mg capsule — dramatically outperformed placebo across every measure of symptom relief in 134 patients aged 12 and older.

The drug not only worked faster, but also helped more patients achieve complete resolution. At 24 hours, 60% of attacks treated with deucrictibant reached complete symptom resolution compared to just 15% with placebo. Rescue medication use was also far lower — only 9% of deucrictibant-treated attacks required it, versus 44% with placebo. The safety profile was reassuring, with no serious or severe drug-related adverse events and no treatment discontinuations.

By the Numbers:

• Median time to symptom relief: 1.28 hrs (deucrictibant) vs. >12 hrs (placebo)
• Symptom relief at 4 hours: 83% vs. 28%
• Complete resolution at 24 hours: 60% vs. 15%
• Rescue medication use: 9% vs. 44%
• FDA target action date: April 23, 2027

Why it matters: If approved, deucrictibant would be the first oral bradykinin B2 receptor antagonist for HAE — offering patients a convenient, fast-acting alternative to injectable therapies during attacks.